| Primary |
| Prostate Cancer Metastatic |
33.1% |
| Product Used For Unknown Indication |
9.2% |
| Prostate Cancer |
8.9% |
| Pain |
6.4% |
| Hypertension |
6.4% |
| Cancer Pain |
5.1% |
| Hormone Therapy |
5.0% |
| Constipation |
3.6% |
| Prophylaxis |
3.0% |
| Back Pain |
2.7% |
| Nausea |
2.4% |
| Medical Diet |
2.3% |
| Vomiting |
2.3% |
| Diabetes Mellitus |
2.2% |
| Metastases To Bone |
1.8% |
| Gastrooesophageal Reflux Disease |
1.2% |
| Breast Cancer Metastatic |
1.1% |
| Anaemia |
1.1% |
| Arthralgia |
1.1% |
| Bone Pain |
1.1% |
|
| Vomiting |
8.6% |
| Dyspnoea |
7.9% |
| Pulmonary Embolism |
7.9% |
| Dehydration |
7.6% |
| Thrombocytopenia |
6.8% |
| Anaemia |
5.8% |
| Sepsis |
5.4% |
| Fatigue |
5.0% |
| Pneumonia |
5.0% |
| Death |
4.0% |
| Hyperuricaemia |
4.0% |
| Hypokalaemia |
4.0% |
| Pyrexia |
4.0% |
| Bone Pain |
3.6% |
| Febrile Neutropenia |
3.6% |
| Haematuria |
3.6% |
| Hypotension |
3.6% |
| Disease Progression |
3.2% |
| Nausea |
3.2% |
| Pain |
3.2% |
|
| Secondary |
| Prostate Cancer Metastatic |
31.5% |
| Product Used For Unknown Indication |
10.2% |
| Prostate Cancer |
8.4% |
| Pain |
6.4% |
| Hypertension |
6.3% |
| Cancer Pain |
5.3% |
| Hormone Therapy |
5.0% |
| Constipation |
3.7% |
| Back Pain |
3.0% |
| Prophylaxis |
2.9% |
| Vomiting |
2.7% |
| Diabetes Mellitus |
2.3% |
| Medical Diet |
2.2% |
| Nausea |
2.2% |
| Metastases To Bone |
1.8% |
| Anaemia |
1.6% |
| Breast Cancer Metastatic |
1.2% |
| Mineral Supplementation |
1.2% |
| Urinary Tract Infection |
1.1% |
| Arthralgia |
1.1% |
|
| Vomiting |
9.9% |
| Dehydration |
8.9% |
| Dyspnoea |
7.0% |
| Pneumonia |
6.4% |
| Pulmonary Embolism |
6.4% |
| Anaemia |
5.4% |
| Muscular Weakness |
4.8% |
| Sepsis |
4.8% |
| Thrombocytopenia |
4.8% |
| Urinary Tract Infection |
4.8% |
| Disease Progression |
4.5% |
| Hypokalaemia |
4.2% |
| Fatigue |
3.8% |
| Haematuria |
3.5% |
| Hepatic Enzyme Increased |
3.5% |
| Hyperuricaemia |
3.5% |
| Hypotension |
3.5% |
| Pyrexia |
3.5% |
| Renal Failure |
3.5% |
| Bone Pain |
3.2% |
|
| Concomitant |
| Product Used For Unknown Indication |
39.3% |
| Pain |
11.9% |
| Prostate Cancer |
11.9% |
| B-cell Small Lymphocytic Lymphoma Stage Ii |
3.6% |
| Constipation |
3.6% |
| Hypertension |
3.6% |
| Arrhythmia |
2.4% |
| Arthralgia |
2.4% |
| Blood Pressure |
2.4% |
| Bone Neoplasm Malignant |
2.4% |
| Depression |
2.4% |
| Gastric Ulcer Haemorrhage |
2.4% |
| Neuropathy Peripheral |
2.4% |
| Sleep Disorder |
2.4% |
| Anaemia |
1.2% |
| Anaemia Of Malignant Disease |
1.2% |
| Chronic Lymphocytic Leukaemia |
1.2% |
| Nausea |
1.2% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.2% |
| Prostate Cancer Metastatic |
1.2% |
|
| Atrial Fibrillation |
14.3% |
| Prostate Cancer |
14.3% |
| Death |
7.1% |
| Disease Progression |
7.1% |
| Hypotension |
7.1% |
| Incorrect Drug Administration Duration |
7.1% |
| Malaise |
7.1% |
| Muscular Weakness |
7.1% |
| Peritonitis |
7.1% |
| Tremor |
7.1% |
| Urinary Incontinence |
7.1% |
| Urticaria |
7.1% |
|
| Interacting |
| Prostate Cancer Metastatic |
25.0% |
| Type 2 Diabetes Mellitus |
25.0% |
| Breast Cancer Metastatic |
18.8% |
| Tuberculosis |
18.8% |
| Hormone Therapy |
6.3% |
| Product Used For Unknown Indication |
6.3% |
|
| Drug Interaction |
33.3% |
| Hypoglycaemia |
33.3% |
| Muscular Weakness |
33.3% |
|
